Clinical trials: Epithelial Tumor, Malignant
Hepatocellular Carcinoma, Pulmonary Metastasis
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization…
- Trial name
- NCT02702323
- Testing
- Apatinib, TACE
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Epithelial Ovarian Cancer, Ovarian Carcinoma
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based…
- Trial name
- NEODOC (NCT05773859)
- Testing
- XP-DC vaccinations
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Nasopharyngeal Neoplasms
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
- Trial name
- ALTER-HN005 (NCT05807880)
- Testing
- The combination treatment of anlotinib, penpulimab and capecitabine.
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00025480
- Testing
- carboplatin, paclitaxel, tipifarnib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-small-cell Lung Cancer, Mesothelioma
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT04489862
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Upper Tract Urothelial Carcinoma
OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma
Upper tract urothelial carcinoma (UTUC) is difficult to stage accurately because cross-sectional imaging and ureteroscopic biopsy may not reliably demonstrate muscular or periureteral invasion.
- Trial name
- NCT07751796
- Testing
- OptiCross HD Coronary Imaging Catheter
- Volunteers
- 15 people
- Sponsor
- Yonsei University
Epithelial Ovarian Cancer, DNA Methylation
Cell-free DNA Methylation for Epithelial Ovarian Cancer
Liquid biopsy is challenging for the diagnosis of epithelial ovarian cancer (EOC). In this study, we performed the methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum to discover the…
- Conditions
- Epithelial Ovarian Cancer, DNA Methylation, Benign Ovarian Tumor, Training Set
- Trial name
- NCT04651946
- Testing
- DNA methylation testing
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Lei Li
Locally Advanced or Metastatic NSCLC
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic…
- Trial name
- NCT05990127
- Testing
- AK104, Tislelizumab, carboplatin
- Where
- 62 sites in China
- Volunteers
- 642 people
- Sponsor
- Akeso
Carcinoma, Non-small-Cell Lung
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
- Trial name
- NCT06116786
- Testing
- JNJ-86974680, Cetrelimab, Radiation Therapy
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Recurrent Ovarian Carcinoma
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection.
- Trial name
- SCENIC (NCT06292286)
- Testing
- Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma, Image-Guided Biopsy
Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis…
- Trial name
- NCT05202626
- Testing
- Nasopharyngeal Endoscopy image-guided Biopsy
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Sciences
Anaplastic Throid Carcinoma
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
- Trial name
- NCT06856278
- Testing
- NKG2D CAR-NK with PD-1 Antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB2 Cervical Cancer AJCC v6 and v7
- Trial name
- NCT01711515
- Testing
- Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy
- Where
- 16 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
The purpose of this study is to determine if a new drug, RO4929097, can work with cetuximab, a drug already approved for colorectal cancer, to help fight the patient's cancer.
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01198535
- Testing
- Cetuximab, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Healthy Subject
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer
The goal of this research study is to find out if using additional MRIs and biomarker testing can help researchers learn to predict how the tumor may change during radiation therapy.
- Conditions
- Cutaneous Squamous Cell Carcinoma of the Head and Neck, Healthy Subject, Head and Neck Cancer
- Trial name
- NCT03491176
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Thymoma, Thymic Carcinoma
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients…
- Conditions
- Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
- Trial name
- NCT01025089
- Testing
- Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer, Lung Cancer, Non-Small Cell
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency…
- Trial name
- ALCINA 5 (NCT07060950)
- Testing
- Blood sampling C1
- Where
- France
- Volunteers
- 620 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.